Allspring Global Investments Holdings LLC Buys 1,405,085 Shares of Hologic, Inc. $HOLX

Key Points

• Allspring Global Investments Holdings LLC increased its stake in Hologic by 473.5% during the second quarter, acquiring an additional 1,405,085 shares to own approximately 0.76% of the company's stock, valued at $111.18 million.
• Analysts have issued revised price targets for Hologic, with Argus setting a new objective at $90, while UBS and Royal Bank of Canada also raised their targets, indicating a general positive sentiment with a consensus rating of "Moderate Buy".
• In insider news, CEO Stephen P. Macmillan sold 138,358 shares at an average price of $66.97, decreasing his ownership stake by 10.08% to approximately 1.23 million shares.

Allspring Global Investments Holdings LLC raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 473.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,701,820 shares of the medical equipment provider's stock after acquiring an additional 1,405,085 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.76% of Hologic worth $111,180,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Chung Wu Investment Group LLC bought a new position in shares of Hologic in the second quarter worth about $26,000. Zions Bancorporation National Association UT bought a new position in shares of Hologic in the first quarter worth about $34,000. Cromwell Holdings LLC lifted its holdings in shares of Hologic by 307.0% in the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock worth $38,000 after acquiring an additional 436 shares during the last quarter. Allworth Financial LP raised its holdings in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in Hologic in the 1st quarter valued at approximately $42,000. Institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

HOLX has been the subject of a number of research reports. Argus raised their price objective on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a report on Friday, September 19th. Stephens reiterated an "overweight" rating and issued a $78.00 price objective on shares of Hologic in a report on Thursday, September 18th. UBS Group raised their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their price objective for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $80.15.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.88% of the stock is currently owned by company insiders.

Hologic Stock Performance

NASDAQ:HOLX opened at $65.51 on Tuesday. The company has a market capitalization of $14.57 billion, a PE ratio of 27.18, a P/E/G ratio of 2.32 and a beta of 0.63. The company has a 50 day simple moving average of $67.10 and a two-hundred day simple moving average of $63.36. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.